Publications

March 2006 (Revised July 2006)
Supplement

Drug Testing in Nigeria (B)

By: Debora L. Spar

Research Summary

FDA Review Time of New Drug Applications

Study of FDA Review Time of New Drug Applications (NDAs) between 1990-2004. Three main questions are addressed: How the optimal innovation strategy for firms is contingent upon firm status positions in the knowledge domain; how knowledge status both enables and... View Details

March 2010 (Revised May 2012)
Case

Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration

By: Karim R. Lakhani and Paul R. Carlile

This case presents the Myelin Repair Foundation's accelerated research collaboration model for drug discovery. It highlights the challenges of building a multi-disciplinary and multi-institutional research collaboration that is attempting to create a treatment for... View Details

Keywords: Research and Development; Intellectual Property; Risk and Uncertainty; Strategic Planning; Collaborative Innovation and Invention; Health Disorders; Pharmaceutical Industry; Biotechnology Industry; Health Industry

January 2015 (Revised July 2019)
Case

CVS Health: Promoting Drug Adherence

By: Leslie John, John Quelch and Robert Huckman

Email mking@hbs.edu for a courtesy copy.

The case describes a program that CVS Health recently implemented to improve medication adherence, an important problem from a societal, public policy, and firm... View Details

April 1989 (Revised July 1992)
Supplement

Technology Transfer: Anti-Inflammatory Drug (C)

By: Regina E. Herzlinger

Keywords: Health; Pharmaceutical Industry

Find at Harvard

May 2005
Supplement

GlaxoSmithKline: Reorganizing Drug Discovery (B)

By: Robert S. Huckman and Eli Strick

Supplements the (A) case. View Details

Keywords: Mergers and Acquisitions; Decisions; Operations; Performance; Research and Development; Restructuring; Organizations; Pharmaceutical Industry

14 Nov 2019
Video

Health Minute: The Real Impact of Coupons on Drug Pricing

Web

Drug & Alcohol Policy | About

Drug & Alcohol Policy Overview of HBS Substance Abuse Policies and Procedures Harvard Business School’s policy on drugs and alcohol—adapted from and in accordance with other similar policies at Harvard... View Details

April 1989 (Revised July 1992)
Supplement

Technology Transfer: Anti-Inflammatory Drug (B)

By: Regina E. Herzlinger

Keywords: Health; Pharmaceutical Industry

Find at Harvard

25 Sep 2017
News

When a Drug Coupon Helps You but Hurts Fellow Citizens

01 Mar 2011
News

Fixing What Ails the Drug Industry

echoed Hamburg’s call for improvements in regulation, but he also emphasized the innovation side of the balancing act between safety and product development. “Reinvent invention,” he told the audience. The industry must get smarter about developing View Details

Keywords: pharmaceutical research; Health, Social Assistance

25 Nov 2015
News

Pfizer-Allergan Merger Won't Lead to New, Innovative Drugs

Article

Assessing the Food and Drug Administration's Risk-Based Framework for Software Precertification with Top Health Apps in the United States: Quality Improvement Study

By: Noy Alon, Ariel Dora Stern and John Torous

BACKGROUND: As the development of mobile health apps continues to accelerate, the need to implement a framework that can standardize categorizing these apps to allow for efficient, yet robust regulation grows. However, regulators and researchers are faced with numerous... View Details

Keywords: Mobile Health; Smartphone; Food And Drug Administration; Risk-based Framework; Health Care and Treatment; Mobile and Wireless Technology; Applications and Software; Framework

Read Now

October 2010 (Revised November 2010)
Background Note

Plavix: Drugs in the Age of Personalized Medicine

By: Richard G. Hamermesh, Mara G. Aspinall and Rachel Gordon

PIavix, one of the world's best selling drugs in 2010, appears to have a limited future. Its patent was due to expire soon, and recently new data had been discovered that indicated that a small subset of the population would be at risk for stroke, heart attack, or even... View Details

Keywords: Health Care and Treatment; Product Positioning; Business and Government Relations; Genetics; Competitive Strategy; Pharmaceutical Industry

06 Sep 2022
Research & Ideas

Curbing an Unlikely Culprit of Rising Drug Prices: Pharmaceutical Donations

Prescription drug costs continue to climb in the United States, but tightening a loophole in a federal law may help curb rising expenses, according to research published this week in Health Affairs. Efforts to control US health care... View Details

Keywords: by Ben Rand; Insurance; Health; Pharmaceutical

January 2023
Case

Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery

By: Regina Herzlinger and Brian Walker

What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful... View Details

Keywords: Product Development; Leadership; Health Testing and Trials; Research and Development; Risk and Uncertainty; Financial Condition; Partners and Partnerships; Pharmaceutical Industry

July 2010
Case

Metabical: Positioning and Communications Strategy for a New Weight Loss Drug

By: John A. Quelch and Heather Beckham

Cambridge Sciences Pharmaceuticals (CSP) expects final approval for its revolutionary weight loss drug, Metabical. Metabical will be the only weight loss drug with FDA approval that is also clinically proven to be effective for moderately overweight people. Barbara... View Details

Keywords: Product Positioning; Marketing Communications; Product Launch; Consumer Behavior; Pharmaceutical Industry; United States